Výsledky vyhledávání - "Marie-Noelle Bizot"

Pharmacokinetics of the Oral Direct Renin Inhibitor Aliskiren in Combination With Digoxin, Atorvastatin, and Ketoconazole in Healthy Subjects: The Role of P-Glycoprotein in the Disposition of Aliskiren

Autor: William P. Dole, Gian Camenisch, Helmut Schuetz, Ching-Ming Yeh, Dan Howard, Sujata Vaidyanathan, Christine Reynolds, Marie-Noelle Bizot, Hans Armin Dieterich

Publikováno v: The Journal of Clinical Pharmacology. 48:1323-1338

This study investigated the potential pharmacokinetic interaction between the direct renin inhibitor aliskiren and modulators of P-glycoprotein and cytochrome P450 3A4 (CYP3A4). Aliskiren stimulated in vitro P-glycoprotein ATPase activity in recombin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2de976b8075a521dd21734f571cf1a5
https://doi.org/10.1177/0091270008323258

Zobrazit plný text záznamu

Pharmacokinetics, Safety, and Tolerability of the Novel Oral Direct Renin Inhibitor Aliskiren in Elderly Healthy Subjects

Autor: William P. Dole, Ching-Ming Yeh, Hans Armin Dieterich, Dan Howard, Sujata Vaidyanathan, Marie-Noelle Bizot, Christine Reynolds

Publikováno v: The Journal of Clinical Pharmacology. 47:453-460

This open-label, multicenter study compared the pharmacokinetics and safety of the oral direct renin inhibitor aliskiren in 29 elderly (>or=65 years) and 28 young (18-45 years) healthy subjects. Plasma drug concentrations were determined for up to 16

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::896a2c04245e1e84dc852ac2df5f27c5
https://doi.org/10.1177/0091270006297921

Zobrazit plný text záznamu

Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers

Autor: Valencia J, Zhao C, William P. Dole, Yeh Cm, Hans Armin Dieterich, Sujata Vaidyanathan, Marie-Noelle Bizot, Denouel J, Charisse Kemp

Publikováno v: International Journal of Clinical Practice. 60:1343-1356

Aliskiren is a novel, orally active direct renin inhibitor that lowers blood pressure alone and in combination with existing antihypertensive agents. As aliskiren does not affect cytochrome P450 enzyme activities, is minimally metabolised, and is not

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::173309e46807095ce1c1ab034d2e0dae
https://doi.org/10.1111/j.1742-1241.2006.01164.x

Zobrazit plný text záznamu

Pharmacokinetic interaction between verapamil and everolimus in healthy subjects

Autor: D. Beyer, M. J. Allison, John M. Kovarik, Marie-Noelle Bizot, Robert Schmouder, Q. Jiang

Publikováno v: British Journal of Clinical Pharmacology. 60:434-437

Aims We sought to define the influence of verapamil, an inhibitor of CYP3A and P-glycoprotein, on the pharmacokinetics of everolimus, a substrate of this enzyme and transporter. Methods This was a two-period, single-sequence, crossover study in 16 he

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7880b153d925785e252b47ecd699bba
https://doi.org/10.1111/j.1365-2125.2005.02434.x

Zobrazit plný text záznamu

Effect of aliskiren, an oral direct renin inhibitor, on the pharmacokinetics and pharmacodynamics of a single dose of acenocoumarol in healthy volunteers

Autor: William P. Dole, Sujata Vaidyanathan, Hans Armin Dieterich, Yeh Cm, Marie-Noelle Bizot, Hsun-Lun Aaron Huang, Dan Howard

Publikováno v: Current medical research and opinion. 24(9)

Aliskiren is a direct renin inhibitor approved for the treatment of hypertension. This study investigated the effects of aliskiren on the pharmacokinetics and pharmacodynamics of a single dose of acenocoumarol in healthy volunteers.This two-sequence,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d900848b5d5b8ecf30fe9aeb77541bb0
https://pubmed.ncbi.nlm.nih.gov/18662494

Zobrazit plný text záznamu

A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with allopurinol, celecoxib and cimetidine in healthy subjects

Autor: Stéphanie Tchaloyan, Marie-Noelle Bizot, Ching-Ming Yeh, William P. Dole, Dan Howard, Hans Armin Dieterich, Surya Ayalasomayajula

Publikováno v: Current medical research and opinion. 24(3)

Aliskiren is the first in a new class of orally effective direct renin inhibitors approved for the treatment of hypertension. This multiple-dose study investigated the potential for pharmacokinetic interactions between aliskiren and three drugs, each

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2946c986630240413ac79f003462590
https://pubmed.ncbi.nlm.nih.gov/18234150

Zobrazit plný text záznamu

Evaluation of pharmacokinetic interactions between vildagliptin and digoxin in healthy volunteers

Autor: William P. Dole, Ron Sabo, Yan-Ling He, Monica Ligueros-Saylan, Gilles-Jacques Riviere, Dan Howard, Gangadhar Sunkara, Selene Leon, Marie-Noelle Bizot

Publikováno v: Journal of clinical pharmacology. 47(8)

Vildagliptin is a novel antidiabetic agent that is an orally active, potent, and selective inhibitor of dipeptidyl peptidase IV, the enzyme responsible for degradation of the incretin hormones. This open-label, randomized, 3-period crossover study in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ef27e014ad0b996e868803e81894736
https://pubmed.ncbi.nlm.nih.gov/17660482

Zobrazit plný text záznamu

Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment

Autor: Hilde Bigler, William P. Dole, Hans Armin Dieterich, Sujata Vaidyanathan, Ching Ming Yeh, Dan Howard, Marie-Noelle Bizot

Publikováno v: Clinical pharmacokinetics. 46(8)

Aliskiren is an orally active direct renin inhibitor approved for the treatment of hypertension. This study assessed the effects of renal impairment on the pharmacokinetics and safety of aliskiren alone and in combination with the angiotensin recepto

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28b39111f6c329fd00b8e15ba45ec4c1
https://pubmed.ncbi.nlm.nih.gov/17655374

Zobrazit plný text záznamu

Pharmacokinetics, safety, and tolerability of the oral Renin inhibitor aliskiren in patients with hepatic impairment

Autor: Ching-Ming Yeh, Hans Armin Dieterich, Marie-Noelle Bizot, Vance Warren, Sujata Vaidyanathan, William P. Dole

Publikováno v: Journal of clinical pharmacology. 47(2)

Aliskiren is the first in a new class of orally active, direct renin inhibitors for the treatment of hypertension. This open-label, nonrandomized, single-center, parallel-group study compared the pharmacokinetics and safety of a single 300-mg oral do

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2354db80c3d74ad18ad54f8cc62cc31c
https://pubmed.ncbi.nlm.nih.gov/17244770

Zobrazit plný text záznamu

Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects

Autor: Yeh Cm, Marie-Noelle Bizot, Jo Jermany, Sujata Vaidyanathan, Riccardo P. Camisasca

Publikováno v: British journal of clinical pharmacology. 62(6)

Aims Aliskiren is the first in a new class of orally effective renin inhibitors for the treatment of hypertension. This study compared the pharmacokinetic and pharmacodynamic properties of aliskiren in Japanese and Caucasian subjects. Methods In this

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e71c7a76dace322abb94092dfc64035b
https://pubmed.ncbi.nlm.nih.gov/17118124

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání